Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis

Lung

Volumn 188, Issue 3, 2010, Pages 247-252

  Ando, Masaru ^a   Miyazaki, Eishi ^a   Ito, Takeo ^a   Hiroshige, Shigeo ^a   Nureki, Shin Ich ^a   Ueno, Takuya ^a   Takenaka, Ryuichi ^a   Fukami, Tetsujiro ^a   Kumamoto, Toshihide ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Biomarkers; High resolution computed tomography (HRCT); Idiopathic pulmonary fibrosis (IPF); Prognostic factor; Vascular endothelial growth factor (VEGF)

Indexed keywords

C REACTIVE PROTEIN; KL 6 PROTEIN; LACTATE DEHYDROGENASE; OXYGEN; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; AREA UNDER THE CURVE; ARTERIAL GAS; ARTICLE; BLOOD GAS ANALYSIS; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS; LUNG CANCER; LUNG FUNCTION TEST; LUNG INTERSTITIUM; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; VASCULOTROPIN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCIN-1; PROGNOSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITAL CAPACITY;

EID: 77954457158     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-009-9223-x     Document Type: Article

References (26)

1. American Thoracic Society (2000) Idiopathic pulmonary fibrosis:diagnosis and treatment. International consensus statement.American Thoracic Society (ATS), and the European RespiratorySociety (ERS). Am J Respir Crit Care Med 161:646-664
2. American Thoracic Society/European Respiratory Society InternationalMultidisciplinary Consensus Classification of the IdiopathicInterstitial Pneumonias (2002) This joint statement of theAmerican Thoracic Society (ATS), and the European RespiratorySociety (ERS) was adopted by the ATS board of directors, June2001 and by the ERS Executive Committee, June 2001. Am JRespir Crit Care Med 165:277-304
3. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD,Schroeder DR, Offord KP (1998) Prognostic significance ofhistopathologic subsets in idiopathic pulmonary fibrosis. Am JRespir Crit Care Med 157:199-203
4. Yokoyama A, Kondo K, Nakajima M, Matsushima T, TakahashiT, Nishimura M, Bando M, Sugiyama Y, Totani Y, Ishizaki T,Ichiyasu H, Suga M, Hamada H, Kohno N (2006) Prognosticvalue of circulating KL-6 in idiopathic pulmonary fibrosis.Respirology 11:164-168
5. Takahashi H, Shiratori M, Kanai A, Chiba H, Kuroki Y, Abe S(2006) Monitoring markers of disease activity for interstitial lungdiseases with serum surfactant proteins A and D. Respirology11(Suppl):S51-S54
6. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M (2006) Increasedlevels of KL-6 and subsequent mortality in patients with interstitiallung diseases. J Intern Med 260:429-434
7. Ward PA, Hunninghake GW (1998) Lung inflammation andfibrosis. Am J Respir Crit Care Med 157:S123-S129
8. Kamp DW (2003) Idiopathic pulmonary fibrosis the inflammationhypothesis revisited. Chest 124:1187-1190
9. Magro CM, Allen J, Pope-Harman A, Waldman WJ, Moh P,Rothrauff S, Ross P Jr (2003) The role of microvascular injury inthe evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol119:556-567
10. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ,Holash J (2000) Vascular-specific growth factors and bloodvessel formation. Nature 407:242-248
11. Koyama S, Sato E, Haniuda M, Numanami H, Nagai S, Izumi T(2002) Decreased level of vascular endothelial growth factor inbronchoalveolar lavage fluid of normal smokers and patients withpulmonary fibrosis. Am J Respir Crit Care Med 166:382-385
12. Cosgrove GP, Brown KK, Schiemann WP, Serls AE, Parr JE,Geraci MW, Schwarz MI, Cool CD, Worthen GS (2004) Pigmentepithelium-derived factor in idiopathic pulmonary fibrosis: a rolein aberrant angiogenesis. Am J Respir Crit Care Med 170:242-251
13. Meyer KC, Cardoni A, Xiang ZZ (2000) Vascular endothelialgrowth factor in bronchoalveolar lavage from normal subjectsand patients with diffuse parenchymal lung disease. J Lab ClinMed 135:332-338
14. Gay SE, Kazerooni EA, Toews GB, Lynch JP 3rd, Gross BH,Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI,Popovich J, Hyzy R, Martinez FJ (1998) Idiopathic pulmonaryfibrosis: predicting response to therapy and survival. Am J RespirCrit Care Med 157:1063-1072
15. Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP,King GL (2000) Vascular endothelial growth factor inducesexpression of connective tissue growth factor via KDR, Flt1, andphosphatidylinositol 3-kinase-akt-dependent pathways in retinalvascular cells. J Biol Chem 275:40725-40731
16. Wang H, Keiser JA (1998) Vascular endothelial growth factorupregulates the expression of matrix metalloproteinases in vascularsmooth muscle cells: role of flt-1. Circ Res 83:832-840
17. Hamada N, Kuwano K, Yamada M, Hagimoto N, Hiasa K,Egashira K, Nakashima N, Maeyama T, Yoshimi M, Nakanishi Y(2005) Anti-vascular endothelial growth factor gene therapyattenuates lung injury and fibrosis in mice. J Immunol 175:1224-1231
18. Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF,Huang XY, Wang T, Wang K, Wang X, Chen L (2009) VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonaryfibrosis in mice. Int Immunopharmacol 9:70-79
19. Thickett DR, Armstrong L, Christie SJ, Millar AB (2001)Vascular endothelial growth factor may contribute to increasedvascular permeability in acute respiratory distress syndrome. AmJ Respir Crit Care Med 164:1601-1605
20. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, HasletonPS, Egan JJ (2004) Angiogenic cytokines in patients with idiopathicinterstitial pneumonia. Thorax 59:581-585
21. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M,Nishimura K, Hiwada K, Kohno N (2002) Comparative study ofKL-6, surfactant protein-A, surfactant protein-D, and monocytechemoattractant protein-1 as serum markers for interstitial lungdiseases. Am J Respir Crit Care Med 165:378-381
22. Kobayashi J, Kitamura S (1996) Serum KL-6 for the evaluation ofactive pneumonitis in pulmonary sarcoidosis. Chest 109:1276-1282
23. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y,YokoyamaA,HamadaH,Fujioka S, HiwadaK(1993) KL-6, a mucinlikeglycoprotein, in bronchoalveolar lavage fluid from patients withinterstitial lung disease. Am Rev Respir Dis 148: 637-642
24. Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS(1997) Pulmonary epithelial cell injury and alveolar-capillarypermeability in berylliosis. Am J Respir Crit Care Med 156:109-115
25. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, SchwarzMI, Brown KK (2003) Changes in clinical and physiologicvariables predict survival in idiopathic pulmonary fibrosis. Am JRespir Crit Care Med 168:538-542
26. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH,Colby TV, Travis WD, Flint A, Toews GB, Lynch JP 3rd,Martinez FJ (2003) Prognostic implications of physiologic andradiographic changes in idiopathic interstitial pneumonia. Am JRespir Crit Care Med 168:543-548 (Pubitemid 37088596)